The IPO lock-up period of France-based ABIVAX Société Anonyme (ABVX) ends tomorrow, i.e. on April 17, 2024.
ABIVAX is a clinical-stage biotechnology company developing therapeutics for chronic inflammatory diseases. Its lead drug candidate is Obefazimod, an orally available small molecule with anti-inflammatory properties.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com